Joseph Roswarski
Overview
Explore the profile of Joseph Roswarski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, et al.
JAMA Oncol
. 2021 Sep;
7(11):1678-1685.
PMID: 34529025
Importance: High-risk smoldering myeloma has a 5-year risk of progression to symptomatic multiple myeloma of approximately 75%. Treatment with lenalidomide decreases the risk of progression; however, novel triplet regimens are...
2.
Kazandjian D, Dew A, Hill E, Ramirez E, Morrison C, Mena E, et al.
Oncologist
. 2021 Feb;
26(4):288-e541.
PMID: 33554406
Lessons Learned: Despite the initial optimism for using immune checkpoint inhibition in the treatment of multiple myeloma, subsequent clinical studies have been disappointing. Preclinical studies have suggested that priming the...
3.
Hightower S, Ellis H, Collen J, Ellis J, Grasso I, Roswarski J, et al.
Thromb Res
. 2020 Jul;
195:69-71.
PMID: 32659463
No abstract available.
4.
Roschewski M, Lionakis M, Sharman J, Roswarski J, Goy A, Monticelli M, et al.
Sci Immunol
. 2020 Jun;
5(48).
PMID: 32503877
Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label...
5.
Arter Z, Miles D, Mignano S, Cordaro D, Roswarski J
Ann Hematol
. 2020 Feb;
99(4):895-896.
PMID: 32055929
No abstract available.
6.
Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg S, et al.
Leuk Lymphoma
. 2019 Jan;
60(8):2062-2066.
PMID: 30626252
To evaluate the feasibility and clinical efficacy of the combination of alemtuzumab with dose-adjusted etoposide/cyclophosphamide/doxorubicin/vincristine/prednisone (DA-EPOCH) as upfront therapy for untreated aggressive T and NK cell lymphomas, a phase 1/2...
7.
Tallant A, Selig D, Wanko S, Roswarski J
BMJ Case Rep
. 2018 Oct;
2018.
PMID: 30279255
The authors present a case of an elderly man with a history of Waldenstrom macroglobulinaemia in remission who presented with progressively worsening gait abnormalities and falls for several months. His...
8.
Goo K, Uy R, Roswarski J
J Oncol Pharm Pract
. 2018 Jun;
25(5):1248-1252.
PMID: 29933727
Azacitidine, a deoxyribonucleic acid hypomethylating agent, is used in the treatment of myelodysplastic syndrome. Common adverse effects of azacitidine include bone marrow suppression, injection site reactions, nausea, vomiting, diarrhea, and...
9.
Carter C, Oronsky B, Roswarski J, Oronsky A, Oronsky N, Scicinski J, et al.
Oncoimmunology
. 2017 Nov;
6(10):e1315486.
PMID: 29123948
Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general,...
10.
Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe E, et al.
Leuk Lymphoma
. 2017 Oct;
59(6):1466-1469.
PMID: 29032710
No abstract available.